Journal
JOURNAL OF IMMUNOLOGICAL METHODS
Volume 397, Issue 1-2, Pages 47-54Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jim.2013.09.003
Keywords
HIV-1; Surface-expressed envelope trimer; Single B cell sort; HIV-1 neutralizing antibodies
Categories
Funding
- National Center for Advancing Translational Sciences (NCATS) [UL1 TR000043]
- National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program
- NIH [AI081677, UM1AI100663]
- Bill and Melinda Gates Foundation [OPP1033115]
- German National Academic Foundation
- German Research Foundation (DFG) [KL 2389/1-1]
- Stavros Niarchos Foundation
- Robert Mapplethorpe Foundation
- Bill and Melinda Gates Foundation [OPP1033115] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
Significant efforts have been made to identify HIV-1 neutralizing antibodies because they are considered to be critical to the design of an effective HIV-1 vaccine. Although soluble HIV-1 envelope proteins can be used for this purpose, these reagents differ from membrane-anchored HIV-1 envelope spike in a number of important ways and display only a subset of its native epitopes. Consistent with this, some broadly neutralizing antibodies preferentially bind cell surface-expressed HIV-1 envelope, but not the soluble protein. Here we report the details of a new method for isolating anti-HIV-1 specific B cells based on capturing cells that produce antibodies to cell surface-expressed gp160 Delta c(BaL). While this method is far less efficient than sorting with soluble envelope proteins, it isolated broadly neutralizing anti-HIV-1 antibodies that bind cell surface-expressed gp160 Delta c(BaL) but not soluble envelope proteins. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available